Lipid CY7
CAT. NO. DC68219Ionizable lipid studied for localized pulmonary mRNA delivery to epithelial, endothelial and immune-cell populations.
View product →Product data
Technical details and supporting files
Specifications
| Property | Value |
|---|---|
| CAS No. | Not assigned |
| Chemical Name | TTP-3 |
| Synonyms | Not reported |
| SMILES | CCCCC/C=C\C/C=C\CCCCCCCC(=O)N(CCCN(C)C)C(C(=O)NCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)C(C)(C)CStructure-derived from the alkene geometry drawn in the cited publication; absolute stereochemistry is not specified. |
| Formula | C51H97N3O4 (calculated from the literature-reported structure) |
| M.Wt | 816.35 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year. In solvent: −80 °C, 6 months; −20 °C, 1 month. Keep sealed and protected from light. |
| Shipping condition | Pure lipid, shipped from Shanghai with ice packs. |
| Publication | Chen J, Zhou M, Dong S, et al. Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis. Science. 2026;393:eaeb0054. DOI: 10.1126/science.aeb0054 |
Documentation
Literature-reported optimized formulation
| Component | mol% | Role |
|---|---|---|
| TTP-3 | 60.0 | Ionizable lipid |
| DOPE | 10.0 | Helper phospholipid |
| β-Sitosterol | 27.5 | Sterol lipid |
| C14-PEG2000 | 2.5 | PEG lipid |
| Total | 100.0 |
Component molecular weights and calculated amounts
| Component | Molecular weight | Reported molar parts | Calculated mass |
|---|---|---|---|
| TTP-3 | 816.35 | 60.0 | Not calculated |
| DOPE | 744.034 | 10.0 | Not calculated |
| β-Sitosterol | 414.71 | 27.5 | Not calculated |
| C14-PEG2000 | Not confirmed | 2.5 | Not calculated |
Composition retained from the cited study below. Calculation aid for research planning. C14-PEG2000 is treated using an approximate average molecular weight; confirm the exact supplier or batch value before use. The result covers lipid component weights only and does not include RNA, buffer, solvent, process loss or N/P ratio.
Reported preparation contextAqueous sup-tRNA in 10 mM citrate buffer (pH 4.0) was mixed with the ethanol lipid phase at a 3:1 aqueous-to-organic volume ratio using a T-junction device. The LNPs were then dialyzed against PBS overnight at 4 °C and concentrated using 100 kDa MWCO filters.
Literature-reported performance for the cited formulation
Fig. S1484.14 ± 2.52%sup-tRNA · mean ± SD
Fig. S14125.97 ± 13.38 nmhydrodynamic · mean ± SD
Fig. 3KSuperiorvs A10-LIN (P = 0.0010) and MC3 (P < 0.0001)
Fig. 4C–E~60%of tRNA_Aptamer-positive lung cells
Fig. 4E~32%tRNA_Aptamer-positive · MC3 ~13%
Fig. 4F22% · 19% · 32%ciliated · club · basal cells
Fig. S18~15%tRNA_Aptamer-positive
Fig. S1454.97 ± 2.60%EE; size 204.40 ± 3.01 nm
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, cell or animal model, and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetChen J, Zhou M, Dong S, et al. Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis. Science. 2026;393:eaeb0054. DOI: 10.1126/science.aeb0054
Formulation: main text and Methods; performance: Fig. 3K, Fig. 4C–F, and supplementary Figs. S13–S14 and S18.
Formulation: main text and Methods; performance: Fig. 3K, Fig. 4C–F, and supplementary Figs. S13–S14 and S18.